Journal
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 94, Issue 6, Pages 875-880Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2008.002691
Keywords
non-Hodgkin's lymphoma; HIV; immunosuppression; CD4 count; cohort study
Categories
Funding
- Medical Research Council, UK [G0000199, G0600337]
- MRC [G0600337, G0200585, MC_U122886351] Funding Source: UKRI
- Medical Research Council [MC_U122886351, G0600337, G0200585] Funding Source: researchfish
Ask authors/readers for more resources
Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals. We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 19962006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%) individuals developed an AIDS-defining lymphoma (258 systemic). Younger age, receipt of highly active antiretroviral therapy and later calendar year were all independently associated with a reduced risk of systemic non-Hodgkin's lymphoma. A lower latest CD4 count was strongly associated with systemic non-Hodgkin's lymphoma, in patients who had (RR per log(2)(cells/mm(3)) higher: 0.62) and had not (0.70) received highly active antiretroviral therapy. Associations with other measures of immunosuppression, including nadir CD4 count, experience and duration of severe immunosuppression, were generally weaker. Earlier highly active antiretroviral therapy initiation and wider access to HIV testing is advocated to reduce the risk of systemic non-Hodgkin's lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available